本帖最后由 老马 于 2012-1-13 21:20 编辑 7 B8 b, A' H: j; g( B8 X2 w* J
$ X+ _7 I$ P4 Y& p8 F, P爱必妥和阿瓦斯丁的比较
2 s; ~( b, K: k/ n0 O; M
) [. a: H( t/ U9 M( j; Mhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/2 ]; P* a: |$ C7 _
; Z2 c1 `- s- D
! p- ?" Y T% N
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/' _. G/ x1 r/ }2 x8 T
==================================================
2 B: O& ^. {6 hOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
+ ~2 W/ @- g6 W& i/ D8 R- t: iPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.$ n H' y% c. J5 c6 o
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
5 u! a+ Y; ]+ M) c! N
|